Pershing Square increases stake in Valeant Pharmaceuticals
The hedge fund management company earlier held a stake of 5.7% in the pharmaceutical firm, which develops and markets prescription and non-prescription products. Valeant’s main drug markets include
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.